JPH0255418B2 - - Google Patents

Info

Publication number
JPH0255418B2
JPH0255418B2 JP9201081A JP9201081A JPH0255418B2 JP H0255418 B2 JPH0255418 B2 JP H0255418B2 JP 9201081 A JP9201081 A JP 9201081A JP 9201081 A JP9201081 A JP 9201081A JP H0255418 B2 JPH0255418 B2 JP H0255418B2
Authority
JP
Japan
Prior art keywords
compound
methylethyl
ethylamino
methanol
methoxyphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP9201081A
Other languages
Japanese (ja)
Other versions
JPS57206652A (en
Inventor
Kunihiro Niigata
Takashi Fujikura
Kazuo Imai
Shinichi Hashimoto
Kazuo Pponda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Priority to JP9201081A priority Critical patent/JPS57206652A/en
Priority to DE19813128117 priority patent/DE3128117A1/en
Priority to GB8122797A priority patent/GB2083022B/en
Priority to CA000382575A priority patent/CA1224494A/en
Priority to IT68052/81A priority patent/IT1172230B/en
Priority to ES504376A priority patent/ES8301882A1/en
Priority to FR8114716A priority patent/FR2487827A1/en
Priority to ES514426A priority patent/ES514426A0/en
Publication of JPS57206652A publication Critical patent/JPS57206652A/en
Priority to US07/307,200 priority patent/US4880841A/en
Priority to US07/569,780 priority patent/US5063246A/en
Publication of JPH0255418B2 publication Critical patent/JPH0255418B2/ja
Priority to US07/737,976 priority patent/US5198587A/en
Granted legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は、下記一般式で示される置換フエニル
エーテル誘導体に関する。 式中、R1,R2,R3,R4,X,mおよびnは
夫々つぎの意味を有する。 R1およびR4:低級アルキル基 R2およびR3:水素原子または低級アルキル基 X:酸素原子 m:1乃至3の整数 n:0,1または2 茲に、上記“低級”の語は、炭素数1乃至5個
を有する直鎖状または分枝状の炭素鎖を意味して
いる。したがつて、低級アルキル基としては、メ
チル基、エチル基、プロピル基、イソプロピル
基、ブチル基、ペンチル基などである。 また、−O−R4は側鎖に対して、オルト、メ
タ、パラのいずれの位置にあつてもよい。さら
に、本発明の化合物〔〕は、塩を形成し、ま
た、不整炭素原子を、有するから、これらの塩、
ラセミ体、ラセミ体の混合物、各光学活性体のす
べてを包含する。 本発明化合物〔〕はα−アドレナリン受容体
遮断作用を有し、圧低下剤として有用な新規化合
物である。 本発明化合物〔〕のα−アドレナリン受容体
遮断作用は次の試験方法によつて測定されたもの
であるが静注で0.001〜0.1mg/Kgで有効である。 α−アドレナリン受容体遮断作用: ウレタンで麻酔し、ペントリニユムで処置した
ラツトで血圧を測定し、フエニレフリン10μg/
Kg(静注)による昇圧作用に対する検体の拮抗作
用を測定した。 本発明化合物〔〕の臨床上の投与は、遊離塩
基としてまたはその酸付加塩として、通常静注ま
たは経口的に行われる。投与は静注の場合1回1
〜150mgを1日数回、経口の場合1回10〜500mgを
1日2〜3回行うのが適当である。 本発明の化合物〔〕は、つぎの方法によつて
製造される。 第1方法 (式中、R1,R2,R3,R4,X,mおよびnは
前記と同じ)。 この方法は、ケトン〔〕アミン〔〕とを縮
合させたのち、生成物〔〕を還元することから
成る化合物〔〕の製造法である。 上記ケトンとアミンとの縮合反応は、両者の反
応対応量を有機溶媒中で接触させることにより行
なわれる。有機溶媒としては、メタノール、エタ
ノール、トルエン、アセトニトリル、テトラヒド
ロフラン等が用いられる。また反応を促進するた
めに、通常加温して行なわれる。 ついで、反応生成物〔〕をそのままあるいは
単離したのち、還元する。還元は、酸化白金、ラ
ネーニツケル等の触媒の存在下水素を通ずるか、
または、水素化ホウ素ナトリウムの如き還元剤を
用いて行なわれる。 生成物は、溶媒抽出、カラムクロマトグラフイ
ー、塩形成等によつて、単離精製される。 第2方法 本発明の目的化合物のうち、nが1又は2であ
る化合物は、nが0の化合物を原料として次式の
反応によつても製造することができる。 上記酸化反応においては、酸化剤の種類等酸化
条件を適宜選択することにより、nが1のメチル
スルフイニル化合物またはnが2のメチルスルホ
ニル化合物を得ることができる。 通常メタノール、エタノール等の有機溶媒中
で、過酸化水素水(10〜50%)、メタ過ヨウ素酸
ナトリウム等の酸化剤で処理すると、スルフイニ
ル化合物(n=1)が得られ、また、蟻酸等の酸
性溶媒中で酸化剤(過酸化水素水等)で処理する
ととスルホニル化合物(n=2)が得られる。 以上、本発明の化合物〔〕の製造方法を説明
したがこれらの製造法で得られる本発明の目的化
合物の主なものは以下の通りである。 4−{2−〔2−(2−メトキシフエノキシ)エ
チルアミノ〕−2−メチルエチル}−2−(メチ
ルチオ)フエネトール 4−{2−〔2−(2−メトキシフエノキシ)エ
チルアミノ〕−2−エチルエチル}−2−(メチ
ルチオ)−アニソール 4−{2−〔2−(2−メトキシフエノキシ)−1
−メチルエチルアミノ〕−2−メチルエチル}−
2−(メチルチオ)−アニソール 4−{2−〔2−(3−メトキシフエノキシ)エ
チルアミノ〕−2−メチルエチル}−2−(メチ
ルチオ)アニソール 4−{2−〔2−(2−メトキシフエノキシ)エ
チルアミノ〕−2−メチルエチル}−2−(メチ
ルスルフイニル)フエネトール つぎに、実施例を挙げて、本発明の目的化合物
およびその製造方法をさらに説明する。 なお、実施例で使用する原料化合物4−メチル
−3−メトキシフエニルアセトンは、つぎの参考
例によつて製造した。 参考例 (i) 塩化第1スズ2水和物84gと氷酢酸320mlを
懸濁撹拌下にほとんど透明に溶解するまで氷冷
しながら塩化水素ガスを導入し、これに3−ク
ロルスルホニル−4−メトキシフエニルアセト
ン14.3gを25〜30℃で加えた。さらに30分間室
温で撹拌した後、濃塩酸320mlに注加して水640
mlで希釈し、クロロホルム400mlで抽出した。
クロロホルム層を水洗後、クロロホルムを留去
して油状の3−メルカプト−4−メトキシフエ
ニルアセトン10gを得た。 (ii) 3−メルカプト−4−メトキシフエニルアセ
トン10g無水炭酸カリウム9g、ヨウ化メチル
42gおよびメチルエチルケトン50mlを含有する
混合物を20時間還流下撹拌し、冷後反応化合物
を過し、液を蒸発乾固した。残留物を酢酸
エチルに溶解し、得られた溶液を水洗後、酢酸
エチルを留去して得られた粗結晶をn−ヘキサ
ン−エーテルで再結晶し、融点74〜75℃の4−
メチル3−メトキシフエニルアセトン9gを得
た。 実施例 1 4−メトキシ−3−メチルチオフエニルアセト
ン8.4gと2−メトキシフエノキシエチルアミン
6.7gおよびメタノール150mlをまぜ、2時間加熱
還流する。反応溶液を10℃以下に冷やし、水素化
ホウ素ナトリウム2.5gをかきまぜながら10℃以
下で加え、さらに室温で3時間かきまぜる。次に
溶媒を減圧下留去して残留物に水を加え、酢酸エ
チルで抽出し、水洗後無水硫酸マグネシウムで乾
燥して溶媒を留去すると油状物が得られた。これ
をシリカゲルカラムクロマトグラフイー(溶出
液;クロロホルム)に付して精製し、融点65〜68
℃の結晶として4−{2−〔2−(2−メトキシフ
エノキシ)エチルアミノ〕−2−メチルエチル}−
2−(メチルチオ)アニソール8.5gを得た。この
750mgをメタノール10mlに溶かし、無水のシユウ
酸90mgをメタノール1mlに溶かした溶液を加え室
温に1夜放置し、析出した結晶を取し、メタノ
ールで再結晶し融点173〜174℃の4−{2−〔2−
(2−メトキシフエノキシ)エチルアミノ)〕−2
−メチルエチル}−2−(メチルチオ)アニソー
ル・シユウ酸塩600mgを得た。この生成物は次の
理化学的性状を有する。 (i) 元素分析値(C22H29NO7Sとして) C(%) H(%) N(%) 計算値 58.52 6.41 3.10 実側値 58.33 5.93 2.97 (ii) 核磁気共鳴スペクトル(CDCl3) δ:1.08(3H,d,C 3−CH) 2.38(3H,s,C 3S− ) 3.78(3H,s,C 3O− ) 3.86(3H,s,C 3O− ) 実施例1と同様にして、次に化合物を得た。
The present invention relates to substituted phenyl ether derivatives represented by the following general formula. In the formula, R 1 , R 2 , R 3 , R 4 , X, m and n each have the following meanings. R 1 and R 4 : lower alkyl group R 2 and R 3 : hydrogen atom or lower alkyl group It means a straight or branched carbon chain having 1 to 5 carbon atoms. Therefore, examples of the lower alkyl group include methyl group, ethyl group, propyl group, isopropyl group, butyl group, and pentyl group. Moreover, -O-R 4 may be located at any of the ortho, meta, and para positions with respect to the side chain. Furthermore, since the compound [] of the present invention forms a salt and has an asymmetric carbon atom, these salts,
It includes racemates, mixtures of racemates, and optically active forms. The compound of the present invention [] has α-adrenergic receptor blocking action and is a novel compound useful as a pressure-lowering agent. The α-adrenergic receptor blocking effect of the compound of the present invention [] was measured by the following test method, and it was found to be effective at doses of 0.001 to 0.1 mg/Kg when administered intravenously. α-Adrenergic receptor blocking effect: Blood pressure was measured in rats anesthetized with urethane and treated with pentrinum, and phenylephrine 10 μg/
The antagonistic effect of the specimen against the pressor effect of Kg (intravenous injection) was measured. The compound of the present invention [ ] is usually administered intravenously or orally as a free base or an acid addition salt thereof. For intravenous administration, administer once once.
It is appropriate to administer up to 150 mg several times a day, or in the case of oral administration, 10 to 500 mg 2 to 3 times a day. The compound [ ] of the present invention is produced by the following method. First method (In the formula, R 1 , R 2 , R 3 , R 4 , X, m and n are the same as above). This method is a method for producing a compound [] which consists of condensing a ketone [] with an amine [] and then reducing the product []. The condensation reaction between the ketone and the amine is carried out by bringing corresponding amounts of the two into contact in an organic solvent. As the organic solvent, methanol, ethanol, toluene, acetonitrile, tetrahydrofuran, etc. are used. Further, in order to promote the reaction, the reaction is usually carried out by heating. Then, the reaction product [ ] is reduced as it is or after being isolated. Reduction can be carried out through hydrogen in the presence of a catalyst such as platinum oxide or Raney nickel, or
Alternatively, it may be carried out using a reducing agent such as sodium borohydride. The product is isolated and purified by solvent extraction, column chromatography, salt formation, and the like. Second Method Among the target compounds of the present invention, compounds where n is 1 or 2 can also be produced by the reaction of the following formula using a compound where n is 0 as a raw material. In the above oxidation reaction, a methylsulfinyl compound where n is 1 or a methylsulfonyl compound where n is 2 can be obtained by appropriately selecting oxidation conditions such as the type of oxidizing agent. Usually, when treated with an oxidizing agent such as hydrogen peroxide (10-50%) or sodium metaperiodate in an organic solvent such as methanol or ethanol, a sulfinyl compound (n = 1) is obtained, and formic acid, etc. When treated with an oxidizing agent (hydrogen peroxide, etc.) in an acidic solvent, a sulfonyl compound (n=2) is obtained. The methods for producing the compound of the present invention [] have been described above, but the main target compounds of the present invention obtained by these production methods are as follows. 4-{2-[2-(2-methoxyphenoxy)ethylamino]-2-methylethyl}-2-(methylthio)phenetol 4-{2-[2-(2-methoxyphenoxy)ethylamino] ]-2-ethylethyl}-2-(methylthio)-anisole 4-{2-[2-(2-methoxyphenoxy)-1
-methylethylamino]-2-methylethyl}-
2-(Methylthio)-anisole 4-{2-[2-(3-methoxyphenoxy)ethylamino]-2-methylethyl}-2-(methylthio)anisole 4-{2-[2-(2- Methoxyphenoxy)ethylamino]-2-methylethyl}-2-(methylsulfinyl)phenetol Next, the object compound of the present invention and the method for producing the same will be further explained with reference to Examples. In addition, the raw material compound 4-methyl-3-methoxyphenylacetone used in the examples was manufactured according to the following reference example. Reference example (i) 84 g of stannous chloride dihydrate and 320 ml of glacial acetic acid are suspended and stirred, and hydrogen chloride gas is introduced while cooling on ice until an almost transparent solution is obtained. 14.3 g of enylacetone was added at 25-30°C. After stirring for another 30 minutes at room temperature, add 320 ml of concentrated hydrochloric acid to 640 ml of water.
ml and extracted with 400 ml of chloroform.
After washing the chloroform layer with water, chloroform was distilled off to obtain 10 g of oily 3-mercapto-4-methoxyphenylacetone. (ii) 3-mercapto-4-methoxyphenylacetone 10g anhydrous potassium carbonate 9g, methyl iodide
A mixture containing 42 g and 50 ml of methyl ethyl ketone was stirred under reflux for 20 hours, and after cooling, the reaction compound was filtered off and the liquid was evaporated to dryness. The residue was dissolved in ethyl acetate, the resulting solution was washed with water, the ethyl acetate was distilled off, and the resulting crude crystals were recrystallized from n-hexane-ether to give 4-
9 g of methyl 3-methoxyphenylacetone was obtained. Example 1 8.4 g of 4-methoxy-3-methylthiophenyl acetone and 2-methoxyphenoxyethylamine
Mix 6.7 g and 150 ml of methanol and heat under reflux for 2 hours. Cool the reaction solution to below 10°C, add 2.5 g of sodium borohydride while stirring at below 10°C, and stir for an additional 3 hours at room temperature. Next, the solvent was distilled off under reduced pressure, water was added to the residue, extracted with ethyl acetate, washed with water, dried over anhydrous magnesium sulfate, and the solvent was distilled off to obtain an oil. This was purified by silica gel column chromatography (eluent: chloroform), and the melting point was 65-68.
4-{2-[2-(2-methoxyphenoxy)ethylamino]-2-methylethyl}- as crystals at °C.
8.5 g of 2-(methylthio)anisole was obtained. this
Dissolve 750 mg in 10 ml of methanol, add a solution of 90 mg of anhydrous oxalic acid in 1 ml of methanol, leave at room temperature overnight, collect the precipitated crystals, recrystallize with methanol, and obtain 4-{2 with a melting point of 173-174℃. -[2-
(2-methoxyphenoxy)ethylamino)]-2
-Methylethyl}-2-(methylthio)anisole oxalate (600 mg) was obtained. This product has the following physical and chemical properties. (i) Elemental analysis value (as C 22 H 29 NO 7 S) C (%) H (%) N (%) Calculated value 58.52 6.41 3.10 Actual value 58.33 5.93 2.97 (ii) Nuclear magnetic resonance spectrum (CDCl 3 ) δ: 1.08 (3H, d, C H 3 -CH) 2.38 (3H, s, C H 3 S-) 3.78 (3H, s, C H 3 O-) 3.86 (3H, s, C H 3 O-) The next compound was obtained in the same manner as in Example 1.

【表】 実施例 3 4−{2−〔2−(2−メトキシフエノキシ)エ
チルアミノ〕−2−メチルエチル}−2−(メチル
チオ)アニソール1.8gをメタノール水(5:1)
100mlに0.5Mメタ過ヨウ素酸ナトリウム水溶液
10.5mlを0℃で滴下し、4℃で1夜撹拌した。析
出した結晶を取し、液を減圧下濃縮し残留物
をシリカゲルカラムクロマトグラフイー〔溶出
液;クロロホルム−メタノール(溶量比97:3)〕
に付して精製し、油状の4−{2−〔2−(2−メ
トキシフエノキシ)エチルアミノ〕−2−メチル
エチル}−2−(メチルスルフイニル)アニソール
722mgを得た。これをメタノール10mlに溶かし、
シユウ酸2水和物252mgをメタノール6mlに溶か
した溶液を加え、室温で1夜放置し、析出した結
晶を取してエタノールで再結し、融点172〜174
℃の4−{2−〔2−(2−メトキシフエノキシ)
エチルアミノ〕−2−メチルエチル}−2−(メチ
ルスルフイニル)アニソール・シユウ酸塩700mg
を得た。 この生成物はつぎの理化学的性状を有する。 (i) 元素分析値(C22H29NO8Sとして) C(%) H(%) N(%) 計算値 56.52 6.25 3.00 実側値 56.17 6.25 3.01 (ii) 核磁気共鳴スペクトル(d6−DMSO) δ:1.12(3H,d,C 3−CH) 2.68(3H,s,C 3SO− ) 3.76(3H,s,C 3O− ) 3.84(3H,s,C 3O− ) 実施例 4 4−{2−〔2−(2−エトキシフエノキシ)エ
チルアミノ〕−2−メチルエチル}−2−(メチル
チオ)アニソール塩酸塩1.0gをエタノール30ml
に溶解し、撹拌しながら35%過酸化水素水0.5g
を添加、室温にて18時間かきまぜた後、エタノー
ルを減圧留去、残つたアメ状物を水20mlに分散
し、酢酸エチル100mlにて抽出した。酢酸エチル
層を水20mlにて3度洗滌後、濃塩酸0.2mlにて酸
性化した後、減圧留去し、アメ状物をシリカゲル
カラムクロマトグラフイーに付し、酢酸エチル−
メタノール(容量比4:1)の混合溶媒を用いて
溶出して得たアメ状物にイソプロパノール3mlを
加えて結晶化、取して 4−{2−〔2−(2−エトキシフエノキシ)エ
チルアミノ〕−2−メチルエチル}−2−(メチル
スルフイニル)アニソール塩酸塩0.4gを得た。 このものは次の理化学的性状を有する。 (i) 融点 154〜160℃ (ii) 元素分析値(C21H30NO4SClとして) C(%) H(%) N(%) 計算値 58.93 7.06 3.27 実側値 58.64 7.07 3.41 (iii) 核磁気共鳴スペクトル(CDCl3) δ:2.70(3H,s,C 3−SO) 3.82(3H,s,C 3O−) 4.43(3H,t,C 2O−) 実施例 5 4−{2−〔2−(2−メトキシフエノキシ)エ
チルアミノノ〕−2−メチルエチル}−2−(メチ
ルチオ)アニソール1.8gを氷酢酸18mlに溶かし、
氷冷下に30%過酸化水素1.15gを滴下した。60℃
で1時間加熱後、水100mlを加え、酢酸エチルで
抽出した。酢酸エチル層を水洗した後、無水硫酸
マグネシウムで乾燥し、溶媒を留去後、残留物を
シリカゲルカラムクロマトグラフイー〔溶出液:
クロロホルム−メタノール(容量比97:3)〕に
付して精製し、油状の4−{2−〔2−(2−メト
キシフエノキシ)エチルアミノ〕−2−メチルエ
チル}−2−(メチルスルフオニル)アニソール1
gを得た。これをメタノール10mlに溶かし、無水
のシユウ酸230mgをメタノール2mlに溶かした溶
液に加え、室温で1夜放置して析出した結晶を
取し、メタノールで再結晶して融点194〜195℃の
4−{2−〔2−(2−メトキシフエノキシ)エチ
ルアミノ〕−2−メチルエチル}−2−(メチルス
ルフオニル)アニソール・シユウ酸塩700mgを得
た。この生成物は、次の理化学的性状を有する。 (i) 元素分析値(C22H29NO9Sとして) C(%) H(%) N(%) 計算値 54.65 6.04 2.90 実側値 54.48 6.06 3.09 (ii) 核磁気共鳴スペクトル(d6−DMSO) δ:1.12(3H,d,C 3−CH) 3.16(3H,s,C 3−SO2−) 3.16(3H,s, 3−SO2−) 3.72(3H,s,C 3−O−) 3.92(3H,s,C 3−O−) 実施例5と同様にして次の化合物を得た。
[Table] Example 3 1.8 g of 4-{2-[2-(2-methoxyphenoxy)ethylamino]-2-methylethyl}-2-(methylthio)anisole in methanol water (5:1)
0.5M sodium metaperiodate solution in 100ml
10.5 ml was added dropwise at 0°C, and the mixture was stirred at 4°C overnight. The precipitated crystals were collected, the liquid was concentrated under reduced pressure, and the residue was subjected to silica gel column chromatography [eluent: chloroform-methanol (volume ratio 97:3)]
to obtain oily 4-{2-[2-(2-methoxyphenoxy)ethylamino]-2-methylethyl}-2-(methylsulfinyl)anisole.
Obtained 722mg. Dissolve this in 10ml of methanol,
A solution of 252 mg of oxalic acid dihydrate dissolved in 6 ml of methanol was added, left overnight at room temperature, the precipitated crystals were collected and reconsolidated with ethanol, and the melting point was 172-174.
℃4-{2-[2-(2-methoxyphenoxy)
ethylamino]-2-methylethyl}-2-(methylsulfinyl)anisole oxalate 700mg
I got it. This product has the following physical and chemical properties. (i) Elemental analysis value (as C 22 H 29 NO 8 S) C (%) H (%) N (%) Calculated value 56.52 6.25 3.00 Actual value 56.17 6.25 3.01 (ii) Nuclear magnetic resonance spectrum (d 6 − DMSO) δ: 1.12 (3H, d, CH 3 -CH) 2.68 (3H, s, CH 3 SO-) 3.76 (3H, s, CH 3 O-) 3.84 (3H, s, CH 3 O -) Example 4 Add 1.0 g of 4-{2-[2-(2-ethoxyphenoxy)ethylamino]-2-methylethyl}-2-(methylthio)anisole hydrochloride to 30 ml of ethanol.
Dissolve 0.5 g of 35% hydrogen peroxide solution while stirring.
After stirring at room temperature for 18 hours, the ethanol was distilled off under reduced pressure, the remaining syrupy substance was dispersed in 20 ml of water, and extracted with 100 ml of ethyl acetate. The ethyl acetate layer was washed three times with 20 ml of water, acidified with 0.2 ml of concentrated hydrochloric acid, and then evaporated under reduced pressure.
4-{2-[2-(2-ethoxyphenoxy) 0.4 g of ethylamino]-2-methylethyl}-2-(methylsulfinyl)anisole hydrochloride was obtained. This material has the following physical and chemical properties. (i) Melting point 154-160℃ (ii) Elemental analysis value (as C 21 H 30 NO 4 SCl) C (%) H (%) N (%) Calculated value 58.93 7.06 3.27 Actual value 58.64 7.07 3.41 (iii) Nuclear magnetic resonance spectrum ( CDCl3 ) δ: 2.70 (3H, s, CH 3 -SO) 3.82 (3H, s, CH 3 O-) 4.43 (3H, t, CH 2 O-) Example 5 Dissolve 1.8 g of 4-{2-[2-(2-methoxyphenoxy)ethylamino]-2-methylethyl}-2-(methylthio)anisole in 18 ml of glacial acetic acid,
1.15 g of 30% hydrogen peroxide was added dropwise under ice cooling. 60℃
After heating for 1 hour, 100 ml of water was added and extracted with ethyl acetate. After washing the ethyl acetate layer with water, it was dried over anhydrous magnesium sulfate, the solvent was distilled off, and the residue was subjected to silica gel column chromatography [eluent:
chloroform-methanol (volume ratio 97:3)] to give oily 4-{2-[2-(2-methoxyphenoxy)ethylamino]-2-methylethyl}-2-(methyl sulfonyl) anisole 1
I got g. This was dissolved in 10 ml of methanol, added to a solution of 230 mg of anhydrous oxalic acid dissolved in 2 ml of methanol, left overnight at room temperature, the precipitated crystals were collected, and recrystallized with methanol. 700 mg of {2-[2-(2-methoxyphenoxy)ethylamino]-2-methylethyl}-2-(methylsulfonyl)anisole oxalate was obtained. This product has the following physical and chemical properties. (i) Elemental analysis value (as C 22 H 29 NO 9 S) C(%) H(%) N(%) Calculated value 54.65 6.04 2.90 Actual value 54.48 6.06 3.09 (ii) Nuclear magnetic resonance spectrum (d 6 − DMSO) δ: 1.12 (3H, d, CH 3 - CH) 3.16 (3H, s, CH 3 - SO 2 -) 3.16 (3H, s, H 3 - SO 2 -) 3.72 (3H, s, C H 3 -O-) 3.92 (3H, s, CH 3 -O-) The following compound was obtained in the same manner as in Example 5.

【表】【table】

Claims (1)

【特許請求の範囲】 1 一般式 (式中、R1およびR4は、低級アルキル基を、 R2およびR3は、水素原子または低級アルキ
ル基を、 Xは、酸素原子を、 mは、1乃至3の整数を、 nは、0,1又は2を 各々意味する。) で示される置換フエニルエーテル誘導体。
[Claims] 1. General formula (In the formula, R 1 and R 4 are lower alkyl groups, R 2 and R 3 are hydrogen atoms or lower alkyl groups, X is an oxygen atom, m is an integer from 1 to 3, and n is , 0, 1 or 2 respectively).
JP9201081A 1980-07-29 1981-06-15 Substituted phenyl ether derivative Granted JPS57206652A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP9201081A JPS57206652A (en) 1981-06-15 1981-06-15 Substituted phenyl ether derivative
DE19813128117 DE3128117A1 (en) 1980-07-29 1981-07-16 NEW PHENYL-AETHYLAMINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF
GB8122797A GB2083022B (en) 1980-07-29 1981-07-23 Phenethylamine derivatives and their production
CA000382575A CA1224494A (en) 1980-07-29 1981-07-27 Process of producing novel phenethylamine derivatives
ES504376A ES8301882A1 (en) 1980-07-29 1981-07-28 Process of producing phenethylamine derivatives
IT68052/81A IT1172230B (en) 1980-07-29 1981-07-28 PHENETHYLAMINE DERIVATIVES AND PROCEDURE FOR THEIR PRODUCTION
FR8114716A FR2487827A1 (en) 1980-07-29 1981-07-29 NOVEL DERIVATIVES OF PHENETYLAMINE AND PROCESS FOR THEIR PRODUCTION
ES514426A ES514426A0 (en) 1981-06-15 1982-07-27 A PROCEDURE FOR THE PREPARATION OF A FENETILAMINA DERIVATIVE.
US07/307,200 US4880841A (en) 1980-07-29 1989-02-03 Process of producing phenethylamine derivatives
US07/569,780 US5063246A (en) 1980-07-29 1990-08-21 Phenethylamine derivative compositions and use
US07/737,976 US5198587A (en) 1980-07-29 1991-07-30 Phenethylamine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9201081A JPS57206652A (en) 1981-06-15 1981-06-15 Substituted phenyl ether derivative

Publications (2)

Publication Number Publication Date
JPS57206652A JPS57206652A (en) 1982-12-18
JPH0255418B2 true JPH0255418B2 (en) 1990-11-27

Family

ID=14042505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9201081A Granted JPS57206652A (en) 1980-07-29 1981-06-15 Substituted phenyl ether derivative

Country Status (2)

Country Link
JP (1) JPS57206652A (en)
ES (1) ES514426A0 (en)

Also Published As

Publication number Publication date
ES8306084A1 (en) 1983-05-01
JPS57206652A (en) 1982-12-18
ES514426A0 (en) 1983-05-01

Similar Documents

Publication Publication Date Title
JPS6252742B2 (en)
JPH0123462B2 (en)
EP0373998B1 (en) Propenone oxime ethers, method for their preparation and pharmaceutical compositions containing them
EP0103497A1 (en) Xanthine derivatives, process for their preparation and pharmaceutical compositions containing them
JPH037263A (en) Aminobenzenesulfonic acid derivative
CH495981A (en) 2-oxoindolines bactericides analgesics diuretics
US4880841A (en) Process of producing phenethylamine derivatives
RU2208610C2 (en) Piperazine derivatives, method for their preparing and composition comprising thereof
JPS6176433A (en) Novel chalcone derivative
JP2765876B2 (en) Pyridyl ketoxime ether derivatives
JPH0255418B2 (en)
JP3901239B2 (en) Arylalkane derivatives
US5198587A (en) Phenethylamine derivatives
JPS6213344B2 (en)
JPH09301963A (en) N-benzyldioxothiazolidinylbenzamide derivative and production thereof
EP0178073B1 (en) Amide compounds, process for preparing the same and pharmaceutical compositions containing the same
EP0064006A1 (en) Substituted 2,4-dialkoxybenzenesulfonyl chlorides
JPS6141915B2 (en)
JPS62108867A (en) Production of imidazolyl-methane derivative
JPH0212948B2 (en)
JPH0437073B2 (en)
KR850001761B1 (en) Process of producing sulfamoyl-substituted phenethylamide derivatives
JPS5936630B2 (en) 2-imino-1,3-diazacycloalkane derivative
JPH0627112B2 (en) 6-Substituted azulene derivative sulfonate, antiulcer agent and method for producing the same
HU196363B (en) Process for production of new aryl-sulphon compositions and medical preparatives containing them as filling material